LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

Strona główna・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

SectorHealthcare

11.65 2.46

Buy Sell

Overview

Share price change

24h

Current

Min

11.17

Max

11.84

Key metrics
By Trading Economics
Income	11M -20M
Sales	5.9M 40M
Profit margin	-49.569
Employees	184
EBITDA	16M -19M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+89.22% upside

Dividends
By Dow Jones
Next Earnings	24 lut 2026

Market Stats
By TradingEconomics
Market Cap	417M 1.2B
Previous open	9.19
Previous close	11.65

News Sentiment

By Acuity

50%

141 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 lut 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 lut 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 lut 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 lut 2026, 23:21 UTC

Earnings

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 lut 2026, 23:20 UTC

Earnings

Nickel Industries 2025 Operating Profit US$126.4 Million

22 lut 2026, 23:19 UTC

Earnings

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 lut 2026, 23:19 UTC

Earnings

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 lut 2026, 23:18 UTC

Earnings

Nickel Industries Won't Pay a Final Dividend

22 lut 2026, 23:16 UTC

Earnings

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 lut 2026, 21:35 UTC

Earnings

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 lut 2026, 21:34 UTC

Earnings

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 lut 2026, 21:34 UTC

Earnings

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 lut 2026, 21:33 UTC

Earnings

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 lut 2026, 21:33 UTC

Earnings

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 lut 2026, 21:28 UTC

Earnings

Ampol Final Dividend A$0.60/Share

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Revenue A$31.37 Billion, Down 10%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 lut 2026, 14:31 UTC

Acquisitions, Mergers, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 lut 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 lut 2026, 23:12 UTC

Acquisitions, Mergers, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 lut 2026, 22:12 UTC

Earnings

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 lut 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 lut 2026, 21:23 UTC

Earnings

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 lut 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 lut 2026, 21:01 UTC

Acquisitions, Mergers, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 lut 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

89.22% upside

12 Months Forecast

Average 22.29 USD 89.22%

High 29 USD

Low 16 USD

Based on 8 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

141 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.